Navigation Links
Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty
Date:2/15/2012

PITTSBURGH, Feb. 15, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it plans to change the name of its fully integrated branded specialty pharmaceutical business from Dey Pharma to Mylan Specialty.

Mylan CEO Heather Bresch said: "In 2007, we united legacy Mylan, Matrix Laboratories and the generics business of Merck KGaA, which included the acquisition of our specialty subsidiary Dey Pharma, and transformed Mylan into the diversified, global business we are today. Over the past four years, Dey's strong performance has played an important role in our successful transformation and continues to be a valuable growth driver for Mylan."

Bresch continued: "The name change to Mylan Specialty is an important milestone and a natural step in our company's evolution.  Bringing Dey under the Mylan brand will align our specialty business even more directly with everything Mylan stands for – innovating to satisfy unmet needs, making reliability and service a habit, doing what's right, not what's easy, and impacting the future through passionate leadership. Further, operating under one brand will allow us to speak with a more unified and powerful voice as we pursue our mission of providing the world's 7 billion people access to high quality medicine."

Mylan Specialty President John Thievon said: "The decision to change our name from Dey to Mylan Specialty underscores Mylan's deep commitment to this business. Further, the name change provides us with the opportunity to fully maximize the power of the Mylan brand, its reputation for quality and service, and its strong relationship with customers around the world."

Dey is conducting business as Mylan Specialty effective immediately; however, Dey Pharma, L.P. will continue to be used as the legal entity until all required transition steps are completed.

Mylan Specialty has corporate offices in Basking Ridge, N.J. The company also has operations in Allen, Texas and Napa, Calif. Mylan Specialty has approximately 725 employees who work collaboratively on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, severe allergic reactions and psychiatric disorders.

About Mylan

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Actively Addressing Shortage of Preservative-Free Methotrexate Injection
2. Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers
3. Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
4. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
5. Mylan Receives Tentative FDA Approval for Generic Version of Lipitor®
6. Mylan to Host Investor Day on Feb. 21, 2012, in New York City
7. Mylan Launches Innovative Version of Antiepileptic Drug Levetiracetam
8. Mylan Launches First Generic Version of Teveten® Tablets
9. Mylan Receives Approval for First-to-File Generic Keppra XR® Extended-Release Tablets
10. Mylan Receives WHO Approval for Innovative Second-Line-in-a-Box HIV/AIDS Treatment
11. Mylan Launches Generic Version of Toprol-XL® Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):